Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← SearchNorthwestern2023Affirmative
Opening Word document…

The CP solves costs better than the plan---it uses the massive market power of a large government-run risk pool to negotiate down prices, and creates an incentive for private plans to negotiate prices even lower---we have empirics on our side because the most efficient Medicare Advantage private plans already deliver costs lower than Medicare rates

Jacob S. Hacker 18, the Stanley Resor Professor of Political Science at Yale University, 1/3/18, “The Road to Medicare for Everyone,” http://prospect.org/article/road-medicare-everyone

In short, opening up Medicare to everyone would deliver what’s most inspiring about single-payer—health care as a basic right of citizenship. Yet it wouldn’t require replacing employment-based health insurance in one fell swoop. That’s because a large share of employers now providing health benefits would likely continue to do so.

After all, the penalty in the ACA is modest compared with the cost of benefits, but most larger employers still offer health insurance. Some might feel less compunction about paying the fee if it were a contribution rather than a penalty. Some might not want to upgrade their plans to match Medicare Part E. But previous estimates of play-or-pay plans suggest that at any contribution rate close to the House plan’s, most employers providing coverage would continue providing coverage.

Medicare Part E would also begin to deliver on Medicare for All’s second promise—lower prices. For one, more people would be covered by Medicare, which would mean more services financed at Medicare rates. For another, private plans would face competitive pressure to demand better prices so their customers wouldn’t switch to Part E.

At the same time, Medicare should be allowed to bargain for lower prescription drug prices as do other rich nations. Americans pay far higher prices for drugs than do citizens abroad, despite the fact that much of the investment in new drug development begins in U.S. federal R&D spending. The Medicare Part D benefit enacted in 2003 by President George W. Bush and a Republican congressional majority explicitly barred Medicare from providing drug coverage directly (it vested this responsibility in regulated private plans)—precisely because drug manufacturers knew they would be required to bring down their prices if it did. Drug coverage should be part of the basic Medicare package, for young and old alike.

Private insurance plans that participate in Medicare Advantage should also be required to offer coverage to both old and young. Medicare patients like these options, and younger Americans will want them, too. No less important, private insurers are deeply invested in Medicare Advantage. Ensuring they would still have a role—especially when it is lessened in other parts of the market—would reduce their inevitable opposition.

So too, of course, would ensuring that large employers still have the option and incentive to provide private coverage. (Most large employers pay medical claims directly—a practice known as “self-insurance”—but they often contract with large insurers to manage the benefits). Indeed, this system might even be more attractive than the ACA to the largest insurers, which have not shown much interest in the ACA marketplaces.

Many policy experts are critical of Medicare Advantage, because private plans have tended to skim off the healthiest Medicare patients. But the program was improved by the ACA, which reduced the payments to health plans to better reflect the actual cost of providing benefits to enrollees. Moreover, the playing field between Medicare and private plans would be even more level if Medicare could provide drug coverage directly. Today, only Medicare Advantage plans are allowed to cover prescription medicine alongside other services, which is one big reason beneficiaries enroll in them. Sweeten traditional Medicare, and private plans will lose this unfair advantage.

According to recent studies, the most efficient Medicare Advantage plans are already delivering Medicare’s core benefits for less than Medicare can. This is, in large part, because these plans operate in a market in which their main competitor is Medicare, with its relatively low rates. Thus, they can pay rates close to Medicare’s, and still get providers to participate in their networks. (This, by the way, is one reason why privatizing Medicare would be a disaster; without the bargaining clout of the traditional program, private plans would be paying the exorbitant prices they pay in the rest of the market.)

Medicare Part E could even give private plans additional leverage over providers. This idea is counterintuitive—wouldn’t a bigger public program just shift costs onto the private sector?—but it’s borne out in the experience of Medicare Advantage. And if Medicare covered more Americans younger than 65, this dynamic could play out in the rest of the market, too. After all, even the most consolidated and costly provider systems accept Medicare rates for older patients. Once Medicare Part E entered the mix, these lower rates would be paid on behalf of many younger Americans, too. For providers, the alternative to private payments would increasingly be Medicare rates for younger as well as older patients. As a result, private plans would be able to lower what they paid for nonelderly patients and still attract providers.

Sign in to recut, update, or save this card.